Inflammatory Bowel Disease Treatment Market Dynamics, Understanding Patient Needs And Preferences

The global inflammatory bowel disease treatment market size was estimated at USD 20.74 billion in 2023 and is projected to grow at a CAGR of 3.8% from 2024 to 2030. The rising prevalence of ulcerative colitis and Crohn's disease across the globe and increasing approval of novel therapeutics are anticipated to drive the market during the forecast period. Moreover, an increase in the adoption of biological drugs and a surge in government initiatives to improve healthcare services for patients with inflammatory bowel disease (IBD), as these patients are more susceptible to acquiring infections owing to immunosuppressive therapies, further support the market expansion.

The rising prevalence of ulcerative colitis and Crohn's disease is anticipated to fuel the growth of the inflammatory bowel disease treatment market. According to EFCCA, around 10 million people are living with inflammatory bowel diseases worldwide, and the incidence of the disease is expected to increase over the forecast period. Similarly, a study published by the Crohn's & Colitis Foundation in July 2023 estimated that 721 per 100,000 Americans were diagnosed with inflammatory bowel disease. Moreover, in September 2023, NCBI published that more than 320,000 people in Canada will have IBD in 2023, and it is expected to reach 470,000 IBD patients by 2035 in the country.

The upcoming product launches and a strong product pipeline will drive market growth. For instance, in April 2023, AbbVie Inc. received the European Commission (EC) approval for Rinvoq (upadacitinib) to treat moderate to severe Crohn's disease in adult patients. Current therapies focus on reducing inflammation, risks of complications, and long-term remission. Moreover, hospitals & healthcare institutes are working closely with pharmaceutical companies to conduct clinical trials and ensure the safety of patients. Such initiatives are expected to increase research activities and develop a novel treatment for IBD.

The leading participants in the IBD treatment market emphasize adopting advanced technologies like AI for drug discovery and offering new treatments for Crohn's disease and ulcerative colitis. For instance, in December 2023, Insilico Medicine dosed the first patients with its ISM5411, an investigational IBD drug candidate designed using generative artificial intelligence. Moreover, leading companies and tech innovators are collaborating to leverage each other's technologies and competencies to innovate novel regimens and strengthen their position. For instance, in May 2021, CytoReason, an Israel-based tech company, announced a partnership with Ferring Pharmaceuticals to accelerate the drug development process and innovate novel therapeutics for IBD using AI technology.

Order a free sample PDF of the Inflammatory Bowel Disease Treatment Market Intelligence Study, published by Grand View Research.

Recent Developments

• In May 2024, Johnson and Johnson Services Inc., announced the first phase 3 results for Tremfya’s Crohn’s disease program. The data from phase 3 trial demonstrated that Tremfya is superior to Stelara in all the endoscopic patients in the trial pool.

• In April 2024, Takeda Pharmaceutical Company Limited received FDA approval for subcutaneous administration of Entyvio post-induction therapy with IV Entyvio. The drugs are used to treat patients with severely active Crohn’s Disease.

• In October 2023, Johnson & Johnson Services, Inc. announced the data from a phase 3 clinical trial of Tremfya (guselkumab), studying the safety and efficacy of the drug for active ulcerative colitis. The study showed a 77% overall clinical response rate and early symptom improvement in UC patients.

• In June 2023, Lilly's Omvoh (mirikizumab) received market authorization from UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of ulcerative colitis.

• In February 2023, AbbVie announced that the UK's MHRA approved RINVOQ, a JAK inhibitor, for treating patients with moderate to severe Crohn's disease who had an inadequate response to conventional therapy.

• In January 2023, Inotrem, a clinical-stage biotechnology company, received funding from the Crohn's & Colitis Foundation to help develop novel therapeutic approaches in Crohn's disease and ulcerative colitis.